Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Efavirenz
Drug ID BADD_D00749
Description Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Indications and Usage For use in combination treatment of HIV infection (AIDS)
Marketing Status Prescription; Discontinued
ATC Code J05AG03
DrugBank ID DB00625
KEGG ID D00896
MeSH ID C098320
PubChem ID 64139
TTD Drug ID D07HVY
NDC Product Code 0056-0470; 65862-049; 0378-2233; 72865-172; 69988-0008; 65862-106; 65862-324; 64220-195; 70518-3258; 64980-406; 53104-7544; 69097-301; 64380-889; 70966-0025; 65015-641; 70366-002; 31722-504; 70518-1100; 65862-105; 65015-868; 70518-2962; 67835-0001; 51407-382; 65862-267; 0056-0510; 48087-0062; 48087-0128; 42543-889; 65675-1584; 68554-0018; 48087-0131; 65862-104; 65015-836; 12783-0510; 64980-407; 0056-0474; 48087-0127; 68554-0042; 65015-859
Synonyms efavirenz | (s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | efavirenz, (S)-isomer | efavirenz, (R)-isomer | Stocrin | Sustiva | DMP 266 | DMP-266 | L 743726 | L-743726 | L 743,726 | L-743,726
Chemical Information
Molecular Formula C14H9ClF3NO2
CAS Registry Number 154598-52-4
SMILES C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Basedow's disease10.04.08.004; 06.09.04.003; 05.02.02.003--Not Available
Blindness17.17.01.003; 06.02.02.0010.025232%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood bilirubin increased13.03.01.008--
Blood cholesterol13.12.01.014--Not Available
Blood cholesterol increased13.12.01.0020.025232%
Blood creatinine increased13.13.01.004--
Blood glucose increased13.02.02.002--Not Available
Blood triglycerides increased13.12.03.0010.016821%Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Breast enlargement21.05.04.001--Not Available
Cachexia08.01.01.009; 16.32.03.011; 14.03.02.001--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cerebellar syndrome17.02.02.0020.016821%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Cholestasis09.01.01.0010.016821%Not Available
Chromaturia20.02.01.0020.016821%
Chronic lymphocytic leukaemia01.10.06.001; 16.01.06.0010.004388%Not Available
Cleft palate03.04.02.001; 07.05.08.001--Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Congenital central nervous system anomaly17.19.01.003; 03.10.02.0040.033643%Not Available
Constipation07.02.02.001--
Coordination abnormal17.02.02.004--Not Available
Coronary artery disease24.04.04.006; 02.02.01.0010.042054%Not Available
Cough22.02.03.001--
Cryptorchism05.05.02.002; 03.03.01.001; 21.15.01.0010.016821%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 13 Pages